文献速递传染病防控与疫情报告免疫规划

新型土拉弗朗西斯菌减毒活疫苗株接种可保护食蟹猴抵抗吸入性土拉弗朗西斯菌感染

Vaccination with a novel live attenuated strain of Francisella tularensis subsp. tularensis protects cynomolgus macaques against aerosol F. tularensis infection.
PubMed 文献 · Vaccine · 2025-07-23

西方缺乏获批的土拉弗朗西斯菌疫苗,现有候选疫苗对最严重的呼吸道感染保护不佳。本研究在Fischer 344大鼠和食蟹猴中评估新型减毒活疫苗候选株ΔclpB,皮内接种后大鼠可抵抗接种一年后高达100个半数致死量的吸入攻击,食蟹猴可抵抗接种后1个月和3个月至少500个半数致死量的攻击;接种一年后攻击时症状、细菌负荷和组织病理均减轻。

要点

  • ΔclpB皮内接种使大鼠抵抗接种一年后高达100 MLD的吸入性土拉弗朗西斯菌攻击。
  • ΔclpB皮内接种使食蟹猴抵抗接种后1个月和3个月至少500 MLD的吸入攻击。
  • 接种一年后攻击时,食蟹猴症状、细菌负荷和组织病理均减轻。

核心结论

  • ΔclpB皮内接种在大鼠和食蟹猴中均诱导了对吸入性土拉弗朗西斯菌攻击的保护,为后续动物效力评估和临床安全性评价奠定基础。

研究设计与样本

  • 在Fischer 344大鼠和食蟹猴中评估ΔclpB皮内接种后的保护能力,攻击途径为吸入。

主要发现

  • 皮内接种ΔclpB的大鼠在接种一年后经吸入途径攻击,存活于高达100个半数致死量的攻击,并伴有感染临床症状减轻以及肺和脾组织病理和细菌负荷降低。
  • 皮内接种ΔclpB的食蟹猴在接种后1个月和3个月经吸入途径攻击,可抵抗至少500个半数致死量的攻击。
  • 接种一年后攻击时,接种改善了食蟹猴的症状、细菌负荷和组织病理。

局限性

  • 原文指出鉴于土拉热在自然界发病率低,这些研究为ΔclpB的额外动物效力评估和未来临床安全性评价奠定基础。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Licensed vaccines against Francisella tularensis, a public health threat in some parts of the world and a potential bioterrorism agent, are lacking in Western countries. Existing tularemia vaccine candidates have not been promising in protecting against the most serious respiratory form of tularemia infection. Previous studies identified a novel live attenuated vaccine candidate, F. tularensis subsp. tularensis ΔclpB, that protected rodents against aerosol challenge with the most virulent biotype of Francisella. Characterization demonstrated that ΔclpB is amenable to modern manufacturing. Here, we evaluated further ΔclpB's protective capacities in Fischer 344 rats and in cynomolgus macaques. Results demonstrated that rats immunized intradermally with ΔclpB survived aerosol F. tularensis challenge with up to 100 median lethal doses administered one year after vaccination, accompanied by reduced clinical signs of infection as well as reduced histopathology and bacterial burdens in lungs and spleens. Moreover, intradermal ΔclpB vaccination protected macaques against at least 500 MLD of aerosol F. tularensis challenge administered one and three months after vaccination; vaccination ameliorated symptoms, bacterial burdens, and tissue pathology when tested one year after vaccination. Given the low incidence of tularemia in nature, these studies therefore lay the foundation for additional animal-based evaluations of efficacy and future safety evaluation of ΔclpB by clinical studies.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Elkins KL, Mittereder LR, De Pascalis R, et al. Vaccination with a novel live attenuated strain of Francisella tularensis subsp. tularensis protects cynomolgus macaques against aerosol F. tularensis infection. Vaccine. 2025. PMID: 40706508. doi:10.1016/j.vaccine.2025.127523

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。